BLEXRAVO
Live / Allowed — First extension granted (statement of use) (as of 27 May 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 24 Jul 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99301451
- Mark type
- Word mark
- Filed
- 24 Jul 2025
- Published for opposition
- 07 Oct 2025
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 28 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 May 2026 — SOU EXTENSION 1 GRANTED
- 27 May 2026 — SOU EXTENSION 1 FILED
- 27 May 2026 — SOU TEAS EXTENSION RECEIVED
- 02 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 07 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 Oct 2025 — PUBLISHED FOR OPPOSITION
- 01 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Sept 2025 — ASSIGNED TO EXAMINER
- 24 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Jul 2025 — APPLICATION FILING RECEIPT MAILED
- 24 Jul 2025 — NEW APPLICATION ENTERED